EE537 Cost-Effectiveness of Cemiplimab in Patients With Advanced Basal Cell Carcinoma (aBCC) Who Progressed on or Are Intolerant to a Hedgehog Inhibitor (HHI) in Italy

Autor: Paul, E, LaFontaine, PR, Xu, Y, Inocencio, TJ, Atsou, K, D'Avella, MC, Ader, J, Guyot, P, Caisip, C, Quon, P, Chen, CI, Cope, S
Zdroj: In Value in Health December 2022 25(12) Supplement:S161-S161
Databáze: ScienceDirect
Externí odkaz: